China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit
Sep 10, 2009
The Company will participate on China Pharma-Biotech Panel
TAI'AN, Shandong, China, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC: CBPO) (BULLETIN BOARD: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company's management team will attend the upcoming Susquehanna International Group of Companies ("SIG") 3rd Annual Beijing Management Summit, and the Company's CEO, Mr. Colin Zhao, and newly appointed Director of Research and Development, Dr. Vincent Xie, will participate on the China Pharma-Biotech Panel at the conference.
The 3rd Annual Beijing Management Summit is a two-day conference that brings together executives from public and private companies based in China and other emerging Asian economies. The event will showcase leading companies in the Chinese Consumer, Health Care, Internet, and Technology sectors, as well as companies in the IT Services/Outsourcing and Financial Technologies sectors. The event format will consist of one-on-one meetings and company presentations.
The date and location of China Biologic's one-on-one meetings and the China Pharma-Biotech Panel at the SIG 3rd Annual Beijing Management Summit are as follows:
Date: September 16 - 17, 2009 Location: The Grand Hyatt Beijing Hotel 1 East Chang An Avenue Beijing 100738 Panel Schedule: China Pharma-Biotech Panel September 16, 2009 1:05-2:10 PM Beijing Time Drawing Room IV
China Biologic will be available for one-on-one meetings with analysts and portfolio managers during the summit. Interested parties and investors who wish to meet with China Biologic's management may contact email@example.com, phone +1-(646) 701-7445, or contact SIG institutional sales directly. Participation in the SIG 3rd Annual Beijing Management Summit is by invitation only.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.
For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: IR@chinabiologic.com Web: http://www.chinabiologic.com/ Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel: +1-646-213-1909 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com/
SOURCE: China Biologic Products, Inc.
CONTACT: Y. Tristan Kuo, Chief Financial Officer of China Biologic
Products, Inc., +86-538-6202206, IR@chinabiologic.com; or Investors, Crocker
Coulson, President, +1-646-213-1915, email@example.com, or Gary Chin,
+1-646-213-1909, both of CCG Investor Relations